TiumBio Co., Ltd. (321550.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩3,905 (-3.46%) as of
Key statistics
- Market cap
- 117.30B
- Dividend yield
- 0.00%
- 52-week range
- 3,415.00 – 13,700.00
- Beta
- -0.49
- Revenue (TTM)
- 15B
- Profit margin
- -114.10%
- Volume
- 132.65k
About TiumBio Co., Ltd.
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seongnam-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.